Showing 341 - 360 results of 1,775 for search '"Therapy"', query time: 0.09s Refine Results
  1. 341
  2. 342

    The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i> by A. V. Lapshin, M. V. Mayevskaya, V. T. Ivashkin, P. O. Bogomolov, I. G. Nikitin, O. O. Znoyko

    Published 2013-03-01
    “…The 24- week or 48-week antiviral therapy by standard Interferon-α2b and Ribavirin was prescribed to all patients, taking into consideration the genotype of the HCV-infection. …”
    Get full text
    Article
  3. 343

    The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy by M.C. Van Maaren, T.A. Hueting, D.J.P. van Uden, M. van Hezewijk, L. de Munck, M.A.M. Mureau, P.A. Seegers, Q.J.M. Voorham, M.K. Schmidt, G.S. Sonke, C.G.M. Groothuis-Oudshoorn, S. Siesling

    Published 2025-02-01
    “…The previously developed INFLUENCE tool was rebuild, including a recent population and patients who received neoadjuvant systemic therapy (NST). Methods: Women, surgically treated for nonmetastatic breast cancer, diagnosed between 2012 and 2016, were selected from the Netherlands Cancer Registry. …”
    Get full text
    Article
  4. 344
  5. 345
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350

    Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States by Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Q. Wu, Pallavi Patwardhan

    Published 2022-08-01
    “…**Objectives:** Treatment patterns, healthcare resource utilization (HRU), and costs were evaluated among patients with CML who received third or later lines of therapy (3L+), a clinical population that has not been previously well-studied, with unmet treatment needs as TKI therapy has repeatedly failed. …”
    Get full text
    Article
  11. 351
  12. 352
  13. 353
  14. 354
  15. 355

    Goodman and Gilman's manual of pharmacology and therapeutics /

    Published 2023
    Subjects:
    View in OPAC
    Book
  16. 356
  17. 357
  18. 358
  19. 359
  20. 360